Sav Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 26-06-2024
- Paid Up Capital ₹ 2.50 M
as on 26-06-2024
- Company Age 27 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 M
as on 26-06-2024
- Revenue %
(FY 2022)
- Profit -771.03%
(FY 2022)
- Ebitda -106.72%
(FY 2022)
- Net Worth -7.19%
(FY 2022)
- Total Assets -7.61%
(FY 2022)
About Sav Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹7.50 M.
Sunil Aggarwal, Nalin Agarwal, Gauri Goel, and One other member serve as directors at the Company.
- CIN/LLPIN
U74899DL1997PLC090639
- Company No.
090639
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Nov 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sav Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Aggarwal  | Director | 30-Sep-2004 | Current |
| Nalin Agarwal | Director | 28-Jan-2005 | Current |
| Gauri Goel | Director | 28-Jan-2005 | Current |
| Megha Agarwal | Director | 15-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Sav Pharmaceuticals.
Sav Pharmaceuticals Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 771.03% decrease in profit. The company's net worth dipped by a decrease of 7.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sav Pharmaceuticals?
In 2020, Sav Pharmaceuticals had a promoter holding of 60.60% and a public holding of 39.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Deepali Pharmaceuticals Private LimitedActive 23 years 1 month
Nalin Agarwal and Megha Agarwal are mutual person
- J. R. Healthcare Private LimitedActive 11 years 10 months
Nalin Agarwal and Megha Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Allahabad Bank Creation Date: 15 Mar 2015 | ₹7.50 M | Open |
How Many Employees Work at Sav Pharmaceuticals?
Unlock and access historical data on people associated with Sav Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sav Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sav Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
